$3.92▾ 2.97%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Kalaris Therapeutics, Inc. 's earnings-quality signal is not available yet.
Key numbers
Recent news
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders